PA
MLYS icon

Profund Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Profund Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
39,225
-2,759
-7% -$75.7K 0.03% 337
2026
Q1 		$1.14M Sell
41,984
-5,040
-11% -$148K 0.04% 317
2025
Q4 		$1.71M Buy
47,024
+39,768
+548% +$1.59M 0.05% 247
2025
Q3 		$275K Sell
7,256
-4,875
-40% -$105K 0.01% 783
2025
Q2 		$164K Buy
+12,131
New +$176K 0.01% 933

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Profund Advisors's MLYS Position: Q2 2026 in Review

Profund Advisors reduced its Mineralys Therapeutics (MLYS) stake by 6.6% in Q2 2026, selling an estimated $75.7K and leaving 39,225 shares worth $1.06M. The position accounts for 0.03% of the portfolio, ranked #337.

Profund Advisors first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.71M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Profund Advisors held 39,225 shares of Mineralys Therapeutics worth $1.06M as of Q2 2026.
  • Profund Advisors sold 2,759 Mineralys Therapeutics shares in Q2 2026, an estimated $75.7K.
  • Mineralys Therapeutics made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #337 holding.
  • Profund Advisors first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Profund Advisors's Mineralys Therapeutics position peaked at $1.71M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.